“…The therapeutic arsenal available for 0-to 12-year-old patients with AD is limited to topical agents, broad systemic immune suppressants, or both. 4,18 Active development of targeted therapeutics is ongoing for adults and adolescents with AD and will eventually move to children, further necessitating the elucidation of pediatric endotypes at successive preadult age groups to introduce safe, effective, and age-tailored targeted approaches. 19 We compared T-cell memory subset activation and polarized CD4/CD8 subset frequencies within the skin-homing/cutaneous lymphocyte antigen (CLA) 1 and systemic/CLA 2 compartments in the blood of infants and toddlers (0-5 years old), young children (6 to 11 years old), adolescents (12 to 17 years old), and adults (> _18 years old) with moderate-to-severe AD.…”